Related Experiment Videos
Contemporary management of sarcoidosis
Ngu Wah Khine1,2, Sophie Fletcher1,2,3
1Department of Respiratory Medicine, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
Frontiers in Medicine
|August 13, 2026
Summary
This review discusses updated sarcoidosis management, focusing on evolving steroid-sparing and targeted therapies. It highlights recent clinical trial data and future directions toward personalized medicine for this complex granulomatous disease.
Area of Science:
- Immunology
- Pulmonology
- Rheumatology
Background:
- Sarcoidosis is a multisystem granulomatous disease with unpredictable clinical outcomes.
- Current treatment decisions weigh symptom burden, organ involvement, and quality of life.
- Corticosteroids are standard, but long-term toxicity and limited efficacy drive interest in alternatives.
Purpose of the Study:
- To provide an updated overview of contemporary sarcoidosis management.
- To integrate current guidelines, clinical trial data, and novel therapeutic strategies.
- To discuss challenges in monitoring and future personalized medicine approaches.
Main Methods:
- Review of current guideline recommendations.
- Analysis of recent clinical trial data.
- Integration of information on steroid-sparing, biologic, antifibrotic, and targeted therapies.
Main Results:
- A shift in treatment paradigm towards earlier use of methotrexate and evolving steroid-sparing strategies is evident.
- Contemporary management integrates diverse therapeutic options beyond corticosteroids.
- Challenges in disease monitoring and treatment selection persist.
Conclusions:
- Evolving therapeutic strategies, including steroid-sparing and targeted agents, are changing sarcoidosis management.
- Personalized medicine approaches are crucial for optimizing patient outcomes.
- Further research is needed to address current challenges in sarcoidosis care.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:17Pericarditis III: Medical Management
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...